LT5382B - ENANTIOMERISKAI GRYNO MIRTAZAPINO GAVIMO BuDAS - Google Patents
ENANTIOMERISKAI GRYNO MIRTAZAPINO GAVIMO BuDAS Download PDFInfo
- Publication number
- LT5382B LT5382B LT2005107A LT2005107A LT5382B LT 5382 B LT5382 B LT 5382B LT 2005107 A LT2005107 A LT 2005107A LT 2005107 A LT2005107 A LT 2005107A LT 5382 B LT5382 B LT 5382B
- Authority
- LT
- Lithuania
- Prior art keywords
- acid
- mirtazapine
- combination
- compound
- solvent
- Prior art date
Links
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 229960001785 mirtazapine Drugs 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000002253 acid Substances 0.000 claims abstract description 52
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 239000002904 solvent Substances 0.000 claims abstract description 23
- 238000006798 ring closing metathesis reaction Methods 0.000 claims abstract description 20
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 21
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 18
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 claims description 10
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 claims description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 9
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 150000007522 mineralic acids Chemical group 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 230000000707 stereoselective effect Effects 0.000 claims description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- PYZPABZGIRHQTA-MRXNPFEDSA-N [2-[(2s)-4-methyl-2-phenylpiperazin-1-yl]pyridin-3-yl]methanol Chemical compound C1([C@@H]2N(CCN(C2)C)C=2C(=CC=CN=2)CO)=CC=CC=C1 PYZPABZGIRHQTA-MRXNPFEDSA-N 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 239000002585 base Substances 0.000 description 7
- RONZAEMNMFQXRA-MRXNPFEDSA-N esmirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-MRXNPFEDSA-N 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 6
- 239000007858 starting material Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- -1 Conor and Leonard Chemical class 0.000 description 4
- 239000005909 Kieselgur Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- PVNBEADBJHJCRN-PKLMIRHRSA-N [2-[(2s)-4-methyl-2-phenylpiperazin-1-yl]pyridin-3-yl]methanol;oxalic acid Chemical compound OC(=O)C(O)=O.C1([C@@H]2N(CCN(C2)C)C=2C(=CC=CN=2)CO)=CC=CC=C1 PVNBEADBJHJCRN-PKLMIRHRSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- XDJWZONZDVNKDU-UHFFFAOYSA-N 1314-24-5 Chemical compound O=POP=O XDJWZONZDVNKDU-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- PVNBEADBJHJCRN-NTISSMGPSA-N C(C(=O)O)(=O)O.OCC=1C(=NC=CC1)N1[C@@H](CN(CC1)C)C1=CC=CC=C1 Chemical compound C(C(=O)O)(=O)O.OCC=1C(=NC=CC1)N1[C@@H](CN(CC1)C)C1=CC=CC=C1 PVNBEADBJHJCRN-NTISSMGPSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- RONZAEMNMFQXRA-INIZCTEOSA-N LSM-5894 Chemical compound C1C2=CC=CN=C2N2CCN(C)C[C@H]2C2=CC=CC=C21 RONZAEMNMFQXRA-INIZCTEOSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- VMPVEPPRYRXYNP-UHFFFAOYSA-I antimony(5+);pentachloride Chemical compound Cl[Sb](Cl)(Cl)(Cl)Cl VMPVEPPRYRXYNP-UHFFFAOYSA-I 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010641 nitrile hydrolysis reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- VSAISIQCTGDGPU-UHFFFAOYSA-N phosphorus trioxide Inorganic materials O1P(O2)OP3OP1OP2O3 VSAISIQCTGDGPU-UHFFFAOYSA-N 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03102095 | 2003-07-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2005107A LT2005107A (en) | 2006-06-27 |
| LT5382B true LT5382B (lt) | 2006-11-27 |
Family
ID=34042934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2005107A LT5382B (lt) | 2003-07-10 | 2005-12-12 | ENANTIOMERISKAI GRYNO MIRTAZAPINO GAVIMO BuDAS |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8058436B2 (de) |
| EP (1) | EP1656365B1 (de) |
| JP (1) | JP4668184B2 (de) |
| KR (1) | KR20060056315A (de) |
| CN (1) | CN100558722C (de) |
| AR (1) | AR046494A1 (de) |
| AT (1) | ATE433965T1 (de) |
| AU (1) | AU2004255874B2 (de) |
| BR (1) | BRPI0412447A (de) |
| CA (1) | CA2531165C (de) |
| CO (1) | CO5640123A2 (de) |
| CY (1) | CY1109327T1 (de) |
| DE (1) | DE602004021605D1 (de) |
| DK (1) | DK1656365T3 (de) |
| EC (1) | ECSP066271A (de) |
| ES (1) | ES2327123T3 (de) |
| HR (1) | HRP20051019A2 (de) |
| IL (1) | IL172549A0 (de) |
| IS (1) | IS2674B (de) |
| LT (1) | LT5382B (de) |
| LV (1) | LV13441B (de) |
| MX (1) | MXPA06000325A (de) |
| NO (1) | NO20056175L (de) |
| NZ (1) | NZ544360A (de) |
| PE (1) | PE20050323A1 (de) |
| PL (1) | PL1656365T3 (de) |
| PT (1) | PT1656365E (de) |
| RS (1) | RS20050972A (de) |
| RU (1) | RU2352566C2 (de) |
| SG (1) | SG144914A1 (de) |
| SI (1) | SI1656365T1 (de) |
| TW (1) | TWI335915B (de) |
| UA (1) | UA83666C2 (de) |
| WO (1) | WO2005005410A1 (de) |
| ZA (1) | ZA200600019B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102153620A (zh) * | 2005-09-26 | 2011-08-17 | 住友化学株式会社 | 光学活性的哌嗪化合物的制造方法 |
| JP5080050B2 (ja) * | 2005-09-26 | 2012-11-21 | 住友化学株式会社 | 光学活性なピペラジン化合物の製造方法 |
| TW200808804A (en) * | 2006-05-22 | 2008-02-16 | Organon Nv | Mirtazapine for the treatment of neuropathic pain |
| TW200815370A (en) * | 2006-06-16 | 2008-04-01 | Organon Nv | Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine |
| JP5438976B2 (ja) * | 2007-02-09 | 2014-03-12 | 株式会社カネカ | 光学活性２−アリールピペラジン誘導体の製造法 |
| JP5192707B2 (ja) | 2007-03-22 | 2013-05-08 | 住友化学株式会社 | ミルタザピンの製造方法 |
| EP2146993B1 (de) * | 2007-04-11 | 2015-08-05 | Merck Sharp & Dohme B.V. | Methode zur herstellung von mirtazapin |
| US7994314B2 (en) | 2007-04-11 | 2011-08-09 | N.V. Organon | Method for the preparation of an enantiomerically pure benzazepine |
| KR101485418B1 (ko) * | 2013-05-29 | 2015-01-26 | 주식회사 메디켐코리아 | 고순도 미르타자핀의 제조방법 |
| PT3261645T (pt) | 2015-02-27 | 2021-06-17 | Dechra Ltd | Estimulação do apetite, gestão da perda de peso, e tratamento da anorexia em cães e gatos |
| KR102540021B1 (ko) * | 2020-12-02 | 2023-06-07 | (주)유케이케미팜 | 대량 생산에 적합한 미르타자핀의 제조방법 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4062848A (en) | 1975-04-05 | 1977-12-13 | Akzona Incorporated | Tetracyclic compounds |
| WO1999025356A1 (en) | 1997-11-14 | 1999-05-27 | Akzo Nobel N.V. | Use of mirtazapine for treating sleep apneas |
| WO2000062782A1 (en) | 1999-04-19 | 2000-10-26 | Teva Pharmaceutical Industries Ltd. | Novel synthesis and crystallization of piperazine ring-containing compounds |
| WO2001023345A1 (en) | 1999-09-30 | 2001-04-05 | Sumika Fine Chemicals Co., Ltd. | Process for the preparation of a piperazine derivative |
| WO2001058453A1 (en) | 2000-02-11 | 2001-08-16 | Akzo Nobel N.V. | The use of mirtazapine for the treatment of sleep disorders |
| US6376668B1 (en) | 1999-12-13 | 2002-04-23 | Sumika Fine Chemicals Co., Ltd. | Process for preparing pyridinemethanol compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959470A (en) * | 1972-11-28 | 1976-05-25 | Mikhail Davidovich Mashkovsky | Psychotropic medicinal preparation |
| PT95522B (pt) * | 1989-10-05 | 1997-08-29 | Sankyo Co | Processo para a preparacao de novos compostos tetraciclicos com accao anti-alergica e anti-asmatica e de composicoes farmaceuticas que os contem |
| JPH11222407A (ja) * | 1997-11-14 | 1999-08-17 | Sankyo Co Ltd | 新規殺菌剤 |
| US20030069417A1 (en) * | 1999-04-19 | 2003-04-10 | Claude Singer | Novel synthesis and crystallization of piperazine ring-containing compounds |
| US6068695A (en) * | 1999-07-13 | 2000-05-30 | Bayer Corporation | Process for the continuous preparation of quinacridones |
| JP2001342188A (ja) * | 2000-03-27 | 2001-12-11 | Takeda Chem Ind Ltd | 縮合ピラゾール誘導体、その製造法および用途 |
| TW200538100A (en) * | 2004-04-21 | 2005-12-01 | Akzo Nobel Nv | Mirtazapine salts |
-
2004
- 2004-05-07 UA UAA200600274A patent/UA83666C2/ru unknown
- 2004-06-28 TW TW093118845A patent/TWI335915B/zh not_active IP Right Cessation
- 2004-07-05 PT PT04741958T patent/PT1656365E/pt unknown
- 2004-07-05 MX MXPA06000325A patent/MXPA06000325A/es active IP Right Grant
- 2004-07-05 JP JP2006518216A patent/JP4668184B2/ja not_active Expired - Lifetime
- 2004-07-05 HR HR20051019A patent/HRP20051019A2/xx not_active Application Discontinuation
- 2004-07-05 WO PCT/EP2004/051357 patent/WO2005005410A1/en not_active Ceased
- 2004-07-05 SG SG200805127-8A patent/SG144914A1/en unknown
- 2004-07-05 SI SI200431183T patent/SI1656365T1/sl unknown
- 2004-07-05 PL PL04741958T patent/PL1656365T3/pl unknown
- 2004-07-05 KR KR1020067000511A patent/KR20060056315A/ko not_active Abandoned
- 2004-07-05 NZ NZ544360A patent/NZ544360A/en not_active IP Right Cessation
- 2004-07-05 CA CA2531165A patent/CA2531165C/en not_active Expired - Fee Related
- 2004-07-05 AT AT04741958T patent/ATE433965T1/de active
- 2004-07-05 US US10/564,193 patent/US8058436B2/en not_active Expired - Fee Related
- 2004-07-05 RS YUP-2005/0972A patent/RS20050972A/sr unknown
- 2004-07-05 BR BRPI0412447-2A patent/BRPI0412447A/pt not_active IP Right Cessation
- 2004-07-05 ES ES04741958T patent/ES2327123T3/es not_active Expired - Lifetime
- 2004-07-05 RU RU2006103992/04A patent/RU2352566C2/ru not_active IP Right Cessation
- 2004-07-05 DK DK04741958T patent/DK1656365T3/da active
- 2004-07-05 CN CNB2004800194891A patent/CN100558722C/zh not_active Expired - Lifetime
- 2004-07-05 EP EP04741958A patent/EP1656365B1/de not_active Expired - Lifetime
- 2004-07-05 AU AU2004255874A patent/AU2004255874B2/en not_active Expired
- 2004-07-05 DE DE602004021605T patent/DE602004021605D1/de not_active Expired - Lifetime
- 2004-07-07 PE PE2004000653A patent/PE20050323A1/es not_active Application Discontinuation
- 2004-07-08 AR ARP040102412A patent/AR046494A1/es not_active Application Discontinuation
-
2005
- 2005-12-12 LT LT2005107A patent/LT5382B/lt not_active IP Right Cessation
- 2005-12-13 IL IL172549A patent/IL172549A0/en not_active IP Right Cessation
- 2005-12-15 IS IS8184A patent/IS2674B/is unknown
- 2005-12-23 NO NO20056175A patent/NO20056175L/no not_active Application Discontinuation
-
2006
- 2006-01-03 ZA ZA200600019A patent/ZA200600019B/en unknown
- 2006-01-09 EC EC2006006271A patent/ECSP066271A/es unknown
- 2006-01-10 CO CO06001617A patent/CO5640123A2/es not_active Application Discontinuation
- 2006-02-10 LV LVP-06-21A patent/LV13441B/en unknown
-
2008
- 2008-07-02 US US12/667,969 patent/US20100179319A1/en not_active Abandoned
-
2009
- 2009-08-25 CY CY20091100894T patent/CY1109327T1/el unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4062848A (en) | 1975-04-05 | 1977-12-13 | Akzona Incorporated | Tetracyclic compounds |
| WO1999025356A1 (en) | 1997-11-14 | 1999-05-27 | Akzo Nobel N.V. | Use of mirtazapine for treating sleep apneas |
| WO2000062782A1 (en) | 1999-04-19 | 2000-10-26 | Teva Pharmaceutical Industries Ltd. | Novel synthesis and crystallization of piperazine ring-containing compounds |
| WO2001023345A1 (en) | 1999-09-30 | 2001-04-05 | Sumika Fine Chemicals Co., Ltd. | Process for the preparation of a piperazine derivative |
| US6376668B1 (en) | 1999-12-13 | 2002-04-23 | Sumika Fine Chemicals Co., Ltd. | Process for preparing pyridinemethanol compounds |
| WO2001058453A1 (en) | 2000-02-11 | 2001-08-16 | Akzo Nobel N.V. | The use of mirtazapine for the treatment of sleep disorders |
Non-Patent Citations (1)
| Title |
|---|
| DE BOER TH ET AL.: "Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers.", NEUROPHARMACOLOGY, 1988, pages 399 - 408, XP023755747, DOI: doi:10.1016/0028-3908(88)90149-9 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3640962B2 (ja) | ロイコトリエン拮抗物質の調製方法 | |
| AU2004255874B2 (en) | A method for the preparation of enantiomerically pure mirtazapine | |
| JP4906511B2 (ja) | キラルな塩基環状アミドとの塩形成による、場合により置換されたマンデル酸を分割するための方法 | |
| JP2008545683A (ja) | （置換された）（ｒ）−又は（ｓ）−マンデル酸の動的分割のための方法 | |
| EP2146993B1 (de) | Methode zur herstellung von mirtazapin | |
| US20110118467A1 (en) | Process for the preparation of clopidogrel hydrogen sulfate crystalline form i | |
| US6846935B2 (en) | Procedure for the preparation of racemic and enantionmerically pure derivatives of 1,5-diaryl-3-trifluoromethyl-Δ2-pyrazolines | |
| US20050070522A1 (en) | Resolution of a narwedine amide derivative | |
| HK1086841B (en) | A method for the preparation of enantiomerically pure mirtazapine | |
| US6121306A (en) | Method of making (1S, 4R)-1-azabicyclo[2.2.1]heptan-3-one and (1R, 4S), 1-azabicyclo[2.2.1]heptan-3-one | |
| CH685345A5 (it) | Metodo per la preparazione di acido S-(+)-etodolico e di suoi derivati salini. | |
| US20080255348A1 (en) | Method for the preparation of an enantiomer of a tetracyclic benzazepine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC9A | Transfer of patents |
Owner name: N.V.ORGANON, NL Effective date: 20061220 |
|
| MM9A | Lapsed patents |
Effective date: 20120705 |